GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iSpecimen Inc (NAS:ISPC) » Definitions » Total Current Assets

iSpecimen (iSpecimen) Total Current Assets : $8.24 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is iSpecimen Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. iSpecimen's total current assets for the quarter that ended in Dec. 2023 was $8.24 Mil.


iSpecimen Total Current Assets Historical Data

The historical data trend for iSpecimen's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iSpecimen Total Current Assets Chart

iSpecimen Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Assets
Get a 7-Day Free Trial 1.58 3.47 32.95 19.68 8.24

iSpecimen Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.68 15.96 10.97 9.13 8.24

iSpecimen Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

iSpecimen's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

iSpecimen's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


iSpecimen  (NAS:ISPC) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

iSpecimen's Liquidation Value for the quarter that ended in Dec. 2023 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=5.006-6.078+0.75 * 0.728+0.5 * 0
=-0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iSpecimen Total Current Assets Related Terms

Thank you for viewing the detailed overview of iSpecimen's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


iSpecimen (iSpecimen) Business Description

Traded in Other Exchanges
N/A
Address
450 Bedford Street, Lexington, MA, USA, 02420
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
Executives
Benjamin Bielak officer: Chief Information Officer 450 BEDFORD STREET, LEXINGTON MA 02420
Tracy Curley officer: Chief Financial Officer 450 BEDFORD STREET, LEXINGTON MA 02420
Joseph J. Basile director 450 BEDFORD STREET, LEXINGTON MA 02420
Andrew L. Ross director, 10 percent owner 450 BEDFORD STREET, LEXINGTON MA 02420
Gullans Steven R. Ph.d. director C/O EXCEL VENTURE MANAGEMENT, LLC, 800 BOYLSTON ST., STE 2825, BOSTON MA 02199
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090
Obf Investments, Llc 10 percent owner 450 BEDFORD STREET, LEXINGTON MA 02420
Margaret H. Lawrence director 450 BEDFORD STREET, LEXINGTON MA 02420
George H. Scholl director 450 BEDFORD STREET, LEXINGTON MA 02420
Christopher Ianelli director, officer: CEO, President 450 BEDFORD STREET, LEXINGTON MA 02420
Jill Mullan director, officer: COO, Secretary, Treasurer 450 BEDFORD STREET, LEXINGTON MA 02420